Build 'OncoSync'—an AI-driven, closed-loop therapy management platform for ccRCC and other combination immunotherapy regimens. The platform would: 1) Integrate with EHRs, wearables (e.g., continuous glucose monitors for HIF monitoring), and pharmacy systems to dynamically adjust KEYTRUDA/WELIREG dosages in real-time; 2) Use LLMs to parse patient-reported symptoms (e.g., fatigue, nausea) and automatically titrate doses or trigger clinician alerts; 3) Provide a 'digital twin' of the patient’s tumor microenvironment to simulate treatment outcomes; 4) Offer a direct-to-patient app for adherence tracking with gamified rewards (e.g., 'Take your WELIREG today and unlock a $10 gift card'). Monetization via hospital SaaS ($150K/year), pay-per-patient licensing, and partnerships with Merck/Pfizer for co-marketing.

Market Catalyst & News Trigger

"FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)"

The Workflow Friction

Oncologists, hospitals, and patients with clear cell renal cell carcinoma (ccRCC)

Problem Summary

Real-world problem signal validation.

One-Shot MVP Builder Blueprint (48 Hours)

A dashboard showing: 1) Patient vitals and biomarker trends (e.g., HIF levels from bloodwork); 2) Real-time treatment adherence status; 3) AI-recommended dosage adjustments with clinician override; 4) Simulated tumor response curves based on dosing changes. Integrate with Epic/Cerner for EHR data and Apple HealthKit for wearable sync.

Recommended Developer Tech Stack

• Next.js
• TensorFlow
• FastAPI
• PostgreSQL
• Epic EHR API